A phase II randomized, double-blind, placebo-controlled, multicenter, parallel group, proof of concept study of the analgesic effects of RN624 [tanezumab] in adult patients with post-herpetic neuralgia.

Trial Profile

A phase II randomized, double-blind, placebo-controlled, multicenter, parallel group, proof of concept study of the analgesic effects of RN624 [tanezumab] in adult patients with post-herpetic neuralgia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2009 Planned number of patients changed from 129 to 99 as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top